---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-24-000003"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:02:05.031871+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere Q4 net product sales $39.9M, FILSPARI PSFs total 1,452 in 2023; sNDA filing imminent

## Summary
- Net product sales of $39.9M in Q4 2023 ($127.5M FY); driven by FILSPARI launch ($14.7M Q4).
- Q4 2023 net loss $90.2M ($1.18/sh); cash and equivalents $566.9M at Dec 31, 2023.
- Received 459 new patient start forms for FILSPARI in Q4; total 1,452 PSFs since Feb 2023 approval.
- Expects to submit sNDA for full U.S. approval of FILSPARI in IgAN in Q1 2024; CHMP opinion on EU CMA also Q1.
- Pivotal Phase 3 HARMONY study of pegtibatinase in HCU enrolling; topline data expected in 2026.

## SEC filing metadata
- accession: 0001438533-24-000003
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/0001438533-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/tvtx-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-24-000003
- JSON: https://secwatch.observer/filing/0001438533-24-000003.json
- Plain text: https://secwatch.observer/filing/0001438533-24-000003.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported financial results for the quarter and fiscal year ended December 31, 2023.
  - Period: the quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: On February 15, 2024, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/0001438533-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.